Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Berlin – page 98

1 770 clinical trials in Berlin, Germany across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Berlin at a glance
1 770
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

1 770 trials in Berlin

Open in trial search

Testicular seminoma (pure) stage II

Not recruiting

Study on Reduced Intensity Radio-Chemotherapy for Stage IIA/B Seminoma Using Etoposide, Cisplatin, and Carboplatin for Patients with Stage IIA/B Seminoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Swiss Group for Clinical Cancer Research

Narcolepsy

Not recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Endometrial cancer recurrent+4

Not recruiting

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not recruiting

Study Comparing Methylprednisolone Aceponate Ointment and a Drug Combination for Patients with Mild to Moderate Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Methylprednisolone Aceponate
  • Sponsor:Dermapharm AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Non-small cell lung cancer stage III+2

Not recruiting

Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

DNA mismatch repair protein gene mutation+7

Not recruiting

Study on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AIO-Studien gGmbH

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Eosinophilic oesophagitis

Not recruiting

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Chronic obstructive pulmonary disease

Not recruiting

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Berlin

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, including studies of metastatic prostate cancer, colorectal cancer, and innovative approaches for breast cancer treatment.

  • Prostate Cancer Therapeutics
  • Colorectal Cancer Treatment
  • Early-Stage Breast Cancer
  • Bladder Cancer Interventions

Novel combination therapies and targeted treatments are being evaluated to improve patient outcomes across multiple cancer types.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting various viral infections, including studies on respiratory syncytial virus, cytomegalovirus, and herpes zoster.

  • RSV Vaccine Development
  • CMV Prevention
  • Yellow Fever Protection
  • Herpes Virus Management

These trials aim to enhance immune response and provide long-term protection against serious viral infections.

03 Chronic Conditions

Innovative treatments for various chronic conditions, including autoimmune dementia, hypertriglyceridemia, and studies in transplant medicine.

  • Neurological Disorders
  • Metabolic Conditions
  • Organ Transplantation
  • Women's Health

Research focuses on developing targeted therapies and improving treatment outcomes for long-term conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.